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Selectins [endothelial (E), platelet (P), and leucocytes (L)] are a class of cell adhesion
molecules, stimulated in response to inflammation. Pre-eclampsia is characterized by
inflammation, and angiotensin II is pro-inflammatory. We hypothesized that circulating
maternal and fetal concentrations and placental expression of selectins would be
increased in women with pre-eclampsia and would be associated with the angiotensin
receptors (AT1R and AT2R). Maternal and fetal blood and placental tissue was
collected at delivery from White European normotensive controls (n = 17) and
women with pre-eclampsia (n = 17). Soluble (s) E-, P- and L-selectin protein
concentrations were measured by ELISA and placental protein expression was
examined by immunohistochemistry. Maternal sE-selectin concentrations were increased
in pre-eclampsia (P < 0.001); conversely fetal sE- and sP-selectin levels were
lower in pre-eclampsia (P < 0.05 for both). Staining was mainly localized to
the syncytiotrophoblast for all selectins. E-selectin expression was increased, while
P-selectin was decreased in placental from pre-eclampsia (P < 0.05 for both);
no differences were observed for L-selectin expression. Both E- and L-selectin
were positively correlated (P < 0.008; P < 0.02) with AT2R placental expression,
whilst P-selectin was negatively associated with AT1R (P < 0.005), all only in the
pre-eclampsia group. This novel study reports maternal, fetal and placental expression of
selectins in pre-eclampsia. The increased E-selectins reflect the endothelial dysfunction,
characteristic of pre-eclampsia. In contrast, the reduced P-selectins and the positive
association of placental AT2Rs with both E-and L-selectin in pre-eclampsia could be a
protective mechanism to limit the endothelial dysfunction.
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INTRODUCTION
Pre-eclampsia is a pregnancy-specific syndrome characterized by de novo hypertension and
proteinuria after 20 weeks gestation (1). It affects between 2 and 8% of all pregnancies and is
a major cause of both maternal and perinatal morbidity and mortality worldwide (2, 3). The
consequences of pre-eclampsia are not restricted to pregnancy, with both mothers and their
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offspring being at increased in risk of cardiovascular, metabolic
and renal disease in later life (4, 5). The etiology of pre-eclampsia
remains unknown, but endothelial dysfunction due to abnormal
placentation, oxidative stress, extensive leucocyte activation and
inappropriate activation of the renin-angiotensin system (RAS)
appear to be key contributors (6–10). The endothelium is
the main regulator of vascular homeostasis. In addition to
contributing to vasodilation, the intact endothelium also has anti-
aggregatory, anti-inflammatory and anti-proliferative properties
(11). Hypertension is associated with endothelial dysfunction,
which in turn results from a dysregulation of locally-acting
mediators, such as the vasodilators nitric oxide, and prostacyclin
and the vasoconstrictor endothelin, and angiotensin II (Ang II)
The RAS is an important regulator of blood pressure
and is one of the first hormonal systems to recognize
pregnancy (10). Moreover, the RAS also plays a role in various
pathological situations involving regulation of cell proliferation,
inflammation, oxidative stress, and angiogenesis (12, 13). We
have previously demonstrated a disrupted placental RAS in
pre-eclampsia with the angiotensin II type 1 receptor (AT1R),
activation of which results in vasoconstriction, being more highly
expressed in placenta from women with pre-eclampsia (14).
Selectins are type 1 transmembrane proteins and are involved
in leucocyte trafficking, mediating the initial tethering and
rolling interactions between blood and lymphatic organs via
the endothelium (15). Selectins were so named because of their
ability to selectively bind carbohydrate moieties via their ligand
P-selectin glycoprotein ligand-1 (PSGL-1) (15). There are three
types of selectins, endothelial E-, platelets P- and leucocyte
L-selectins; CD62E, CD62P and CD62L, respectively. All 3
selectins are composed of common extracellular domains and
are distinguished from one another by their variable number
of consensus repeats and very different cytoplasmic tails (16).
E-selectin is normally absent from resting endothelium, but
is transcriptionally induced in venules of multiple organs by
inflammatory mediators, such as tumor necrosis factor (TNF)
and IL-1 (17). P-selectin is constitutively synthesized in both
platelets and endothelial cells and stored inWeibel-Palade bodies.
They are rapidly translocated to the surface upon stimulation
with inflammatory mediators, such as thrombin, histamine, and
platelet-activating factor (17).
The shortest selectin molecule, present in leukocytes, is L-
selectin, which, in the microvasculature, facilitates neutrophil
rolling and migration during inflammatory responses (18).
Elevated sE-selectin levels may be indicative of endothelial
cell activation and damage. In addition to the conventional
roles described above, the selectins play an essential role in
human implantation; L-selectin and its ligands participate in
the adhesion of the blastocyst to the endometrium at the
maternal-fetal interface (19). Moreover, P- and E-selectins are
also involved in immune recognition between maternal decidua
and the embedded embryo, as well as trophoblast migration
within decidual spiral arterioles (19). Reduced expression of
all selectins has been reported in both decidual cells in
uterine decidual stroma and in the placenta (cytotrophoblasts
and syncytiotrophoblasts) of early miscarriages (6–11 weeks)
compared to controls (terminations for social reasons) (20).
Concentrations of both soluble (s) E- and P-selectins
have been reported to be increased in patients with chronic
hypertension with the most severe endothelial dysfunction (21).
Previous studies have reported elevated maternal plasma sE-
selectin concentrations in women with pre-eclampsia, both at the
time of delivery (22–26) and also prior to clinical diagnosis (22).
However, the available data concerning both sP- and sL-selectins
(22, 23, 26, 27) are conflicting.
Associations between the RAS and the selectins have
previously been reported: Ang II is a potent stimulus to
angiogenesis, both directly and by supplying angiogenic factors
by platelet aggregation (28) and inducing the expression of P-
selectin on platelets, while lessening its expression in endothelial
cells (29). In addition, platelets express AT1R on their surface,
and AT1R antagonists reduce P-selectin expression in platelets
(30) and inhibit P-selectin-mediated platelet adhesion to the
microvessels (31). Ang II also acts directly on naive T cells
inducing upregulation of L-selectin via the AT1R (32). Finally,
Ang II treatment significantly increased E-selectin mRNA
expression in vascular endothelial cells collected from lung
tissues in a mouse model of pulmonary metastasis (33).
We hypothesized that both soluble and placental expression
of selectins would be increased in women with pre-eclampsia
reflecting the endothelial dysfunction and inflammation
characteristic of the syndrome. These selectins would also be
associated with RAS receptors, contributing to the mechanistic
changes associated with pre-eclampsia. This study therefore
aimed to measure both soluble and placental expression of all
selectins in matched maternal, fetal, and placental samples from
normotensive control women and women with pre-eclampsia.
MATERIALS AND METHODS
Subjects and Sample Collection
The study population consisted of 17 normotensive control
women and 17 women with pre-eclampsia, collected over a
period of 18 months (Table 1). Nottingham University Hospital
Ethics Committee approved the investigations and written
informed consent to participation was obtained from each
woman. Cases were defined on admission with a clinical
diagnosis of pre-eclampsia, defined as a systolic blood pressure
of ≥ 140mm Hg and diastolic pressure (Korotkoff V) of ≥
90mmHg on 2 occasions after 20 weeks’ gestation in a previously
normotensive women and proteinuria > 300 mg/L, 500 mg/day
or 2+ on dipstick analysis of midstream urine (MSU) if 24-h
collection result was not available (1). Although samples were
collected under the criteria defined originally (1), they still fit
the recently updated definition (34). For subgroup analysis, the
pre-eclampsia group was further split by early- (diagnosis ≤
34 weeks) and late- (diagnosis >34 weeks) onset pre-eclampsia
(35). Medical and obstetric histories, including delivery data,
were obtained for each woman. The birthweight centile for each
baby was computed, correcting for gestation age, sex, maternal
parity, and body mass index (BMI) (36). Venous blood samples
were collected before delivery and umbilical venous (fetal) blood
were collected immediately after and processed as previously
described (6); samples were stored in aliquots at −80oC until
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TABLE 1 | Clinical and obstetric data of subject groups*.
Parameter NC (n = 17) PE (n = 17)
Age (yrs) 28.2 ± 7.2 31 ± 6.5
Booking body mass index (Kg/m2 ) 26.4 ± 5.5 24.8 ± 3.5
Smoking status
Non-smoker 9 (53) 11 (65)
Smoker 8 (47) 6 (35)
Parity
Nulliparous 11 (65) 10 (59)
Multiparous 6 (35) 7 (41)
Max. systolic blood pressure
(mmHg)
114 ± 3.8 155 ± 3.8
†
Max. diastolic blood pressure
(mmHg)
75 ± 2.1 97 ± 5.0
†
Proteinuria (g/L) Median [min, max] - 1.0 [0.3, 9.4]
Gestational age at delivery (Wks) 40.0 ± 1.0 37.7 ± 1.8
Mean birthweight (g) 3439 ± 498 2993 ± 735
†
Corrected birthweight centile 27.9 [17.5, 66.8] 35.1 [8.6, 76.3]
Caesarean section 4 (24) 13 (76)
Early-onset PE - 6 (35)
*Data represented as means ± SD or median [IQR] as appropriate, except for smoking
status, parity and Caesarean sections and early-onset PE, which are shown as number
(percentage). NC, normotensive control; PE, pre-eclampsia; BMI, body mass index.
†
P
< 0.05 between normotensive controls and women with pre-eclampsia.
analysis. In addition, placental tissue samples were collected
from a standardized location midway between cord insertion
and placental border and processed for immunohistochemistry
as previously described (6).
Soluble Selectin Assays
Soluble (s) E-, P-, and L-selectin were measured in maternal
and fetal EDTA plasma using ELISAs (KA0116, KA0548,
and KA0117, respectively; Abnova, Taiwan) following the
manufacturers’ instructions. Plasma samples were diluted 1:100,
run in duplicate and blinded to outcome group. Intra- and inter-
assay variations were: sE-selectin: 5.4 and 6%; sP-selectin: 5.5 and
6.1%; sL-selectin: 3.7 and 4.2%.
Placental Selectin Protein
Expression/Localization
Immunohistochemical analysis was performed as previously
described (37), using antibodies to E-selectin (mouse
monoclonal, BBA16; 5µg/mL; R&D Systems), P-selectin
(mouse monoclonal, BBA30; 10µg/mL; R&D Systems) and
L-selectin (rabbit polyclonal, GTX59778; 0.1µg/mL; GeneTex
Inc.). All slides were assessed by the same observer, blinded to
pregnancy outcome. Quantification was performed as described
previously (12), using the Positive Pixel Algorithm of Aperio
ImageScope software; a visual check was also performed to
establish localization of staining. The AT1R and AT2R protein
expression analysis was performed as previously reported (14).
Statistical Analysis
All tests were performed using SPSS version 24. Summary data
are presented as means ± standard deviation (SD) or median
and interquartile range (IQR) as appropriate. The Kolmogorov-
Smirnov test indicated the experimental data were not normally-
distributed. The Kruskal-Wallis test followed by Mann-Whitney
U-test was used for multiple group analysis; the Wilcoxon paired
tests were used for maternal and fetal selectin concentrations.
Potential associations between continuous data were tested
using Spearman’s Rho correlation tests. The null hypothesis was
rejected where P < 0.05.
RESULTS
Subjects
Demographics and clinical characteristics of the participants
are summarized in Table 1. By definition, blood pressures were
significantly increased (P < 0.05) and significant proteinuria was
present in the pre-eclampsia group. Birthweights were also lower
in the women who suffered from pre-eclampsia. The groups
were matched for maternal age, BMI, smoking status, parity, and
gestational age at delivery.
Soluble Selectin Concentrations in
Maternal and Fetal Plasma
Concentrations of all soluble selectins are summarised in
Figure 1. Maternal sE-selectin was increased in pre-eclampsia
compared to controls (P < 0.05; Figure 1A). No significant
differences were observed for sP- or sL-selectins (P > 0.05 for
both; Figures 1B,C). In contrast, in the fetus, both sE- and sP-
selectin concentrations were lower in the pre-eclampsia group (P
< 0.05 for both; Figures 1A,B), but did not differ for sL-selectin
(P > 0.05; Figure 1C).
When comparing paired maternal-fetal samples, both sE- and
sP-selectin concentrations were increased in fetal compared to
maternal plasma only in the normotensive group (P < 0.05 for
both; Figures 1A,B); fetal plasma from women who had pre-
eclampsia remaining similar to their pairedmaternal plasma (P>
0.05). Conversely, fetal sL-selectin concentrations were reduced
compared to their paired maternal samples in both groups (P <
0.05; Figure 1C).
When sub-grouped by early-/late-onset pre-eclampsia, only
maternal sE-selectin concentrations were raised in plasma from
early-onset (n= 6) pre-eclampsia (P = 0.003), compared to both
late-onset (n = 11) pre-eclampsia (P = 0.01) and normotensive
controls (P = 0.002; Figure 1D). No differences were seen for
either sP- or sL-selectin concentrations (P > 0.05 for both; data
not shown).
Ratio between maternal and fetal sE-, sP- and sL-selectin
was calculated (Figure 2). Significantly increased ratios were
observed for both sE- (P = 0.001) and sP- (P = 0.02)
selectin in pre-eclampsia, compared to normotensive controls.
No differences were observed for sL-selectin (P > 0.05).
Placental Selectin Protein Expression
Placental expression of all 3 selectins was determined and
localization was mainly in the syncytiotrophoblast layer,
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FIGURE 1 | Maternal and fetal soluble (s) (A) E-selectin; (B) P-selection and (C) L-selectin concentrations between normotensive control (NC) and pre-eclamptic (PE)
pregnancies. (D) Maternal sE-selectin concentrations when sub-grouped by NC, early-onset PE (diagnosis ≤34 weeks gestation; n = 6) and late-onset PE (>34
weeks gestation; n = 11). Data presented as median [IQR]; *P < 0.05; ***P < 0.0001.
stromal areas and some fetal vessel staining (Figure 3).
Placental E-selectin expression was increased in pre-eclampsia
(median [IQR], positivity; normotensive controls: 0.56
[0.51, 0.65]; pre-eclampsia: 0.71 [0.60, 0.80]; P = 0.008;
Figure 3A), whereas P-selectin was reduced in pre-eclampsia
(normotensive controls 0.47 [0.34, 0.59]; pre-eclampsia 0.35
[0.22, 0.41]; P = 0.008; Figure 3B). E-selectin expression
levels were raised (P = 0.002), while P-selectin expression
was reduced in both the early- and late-onset pre-eclampsia
groups, compared to normotensive control samples (P < 0.05;
Figures 3D,E).
Although no differences were observed between
controls and pre-eclamptic women for L-selectin (P >
0.05; Figure 3C), when sub-grouped by onset of pre-
eclampsia, a significant difference again became apparent
the expression being increased in early-onset pre-eclampsia
group expression compared to both normotensive controls
(P = 0.008) and late-onset pre-eclampsia (P = 0.002;
Figure 3F).
Association of Placental Expression of
Selectins With AT1R and AT2R
We compared placental expression of selectins with
previously measured AT1R and AT2R placental protein
expression. In the pre-eclampsia samples, but not those
from normotensive women, placental expression of both
E-selectin (r = 0.55; P = 0.008; Figure 4A) and L-selectin
(r = 0.61; P = 0.02; Figure 4B) positively correlated
with AT2R expression. In contrast, again only in the
pre-eclampsia group, P-selectin displayed a negative
association with AT1R expression (r = 0.68; P = 0.005;
Figure 4C).
DISCUSSION
This is the first study to present data on all selectins in paired
maternal/fetal plasma together with their placental expression
in women with and without pre-eclampsia. It helps clarify the
conflicting data found previously in relation to P- and L-selectin
in pregnancy and pre-eclampsia.
The increased maternal sE-selectin in pre-eclampsia is in
accordance with previous reports (22, 23, 25, 26). We have
now shown that there is also increased placental E-selectin,
reflecting the overall endothelial dysfunction associated with pre-
eclampsia. Furthermore, the markedly increased concentrations
of maternal sE-selectin, found only in the early-onset pre-
eclampsia group (Figure 1D), presumably reflect the severity of
the syndrome, as has been suggested by others (24). This is
further supported by the finding that sE-selectin is increased
prior to clinical diagnosis of pre-eclampsia (22, 38). Moreover,
Chen et al., have shown that maternal sE-selectin was not
associated with all cases of preterm birth, but specifically only
when complicated by pre-eclampsia (39). The increased placental
E-selectin expression we have shown corresponds with increased
maternal sE-selectin and suggests that the placental dysfunction
contributes to the endothelial damage in pre-eclampsia. Shaw
et al., reported increased E-selectin mRNA expression in
endothelial cell HUVECs and HEECs after incubation with
maternal perfusates obtained from placenta of women with pre-
eclampsia (40), which might amplify the underlying difference.
The interesting finding of reduced fetal sE-selectin in pre-
eclampsia could either be a protective adaptation to limit the
endothelial damage to the fetus, or reflects an underlying inability
to synthesize E-selectin. Since E-selectin can be induced on fetal
endothelial cells to the same extent as adult vessels by 32 weeks’
gestation (17, 41) and the gestational age of the early-onset PE
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FIGURE 2 | Maternal:fetal ratios of soluble (s) (A) E-selectin; (B) P-selection and (C) L-selectin concentrations between normotensive control (NC) and pre-eclamptic
(PE) pregnancies. Data in all box plots are presented as median [interquartile ranges]; **P < 0.001.
FIGURE 3 | Localisation and quantification of placental (A) E-selectin; (B) P-selectin and (C) L-selectin in placenta from normotensive controls (NC (A1, B1, & C1); n
= 17) and pre-eclampsia (PE (A2, B2, & C2); n = 17). Negative controls for each selectins are shown in A3, B3, & C3 respectively. In photomicrographs, positive cells
appear in brown; magnification x400. Scale bars represent 100µm. Protein expression was localized to the syncytiotrophoblast layer (black arrows) and some fetal
vessels (red arrows). (D) E-selectin; (E) P-selectin and (F) L-selectin expression in placenta, when sub-grouped by NC, early-onset PE (diagnosis ≤34 weeks
gestation; n = 6) and late-onset PE (>34 weeks gestation; n = 11). Data in all box plots are presented as median [interquartile ranges]; *P < 0.05; **P < 0.001.
group was nearer 34 weeks, this supports the view that the
difference is attributable to the pre-eclampsia pathology and not
an immaturity of development. sE-selectin also contributes to
homing in the endothelial progenitor cells and promotes tube
formation inmicrovasculature as a repair mechanism (42). Given
that there is reduced tubule formation in HUVECS isolated
from pre-eclamptic pregnancies (43), this further suggests that
the functional capacity of fetal endothelial cells is impaired
in pre-eclampsia.
Nevertheless, the positive correlation with placental AT2R
expression only in the pre-eclamptic samples supports the
hypothesis of a protective mechanism; AT2R forms part of the
“protective” arm of the RAS and is strongly upregulated following
tissue damage such a vascular and neuronal injury (44). AT2R
confers this role through its anti-inflammatory, anti-fibrotic and
anti-apoptotic properties. Moreover, in lung tissues, which have
many parallels with the placenta, Ang II treatment significantly
increased E-selectin mRNA expression in vascular endothelial
cells, further supporting the association (33).
We did not identify any differences in maternal sP-selectin
between groups, which is in contrast to a previous study, which
reported increased levels in pre-eclampsia (23, 26). A potential
explanation for this difference lies in the later gestation age at
sampling in our study when compared to the previous study. The
Frontiers in Medicine | www.frontiersin.org 5 June 2020 | Volume 7 | Article 270
Mistry et al. Selectins, Renin-Angiotensin System and Pre-eclampsia
FIGURE 4 | Scatter plots illustrating the positive relationship between (A) placental E-selectin (r = 0.55; P = 0.008) and (B) L-selectin (r = 0.61; P = 0.02) with
angiotensin type 2 receptor (AT2R) and (C) the negative association between placental P-selectin (r = 0.68; P = 0.005) with angiotensin type 1 receptor (AT1R).
lack of differences in sP-selectins between groups could have been
due to our not measuring platelet sP-selectin levels. Nevertheless,
by using whole plasma, we were able to measure all 3 selectins.
As with sE-selectins, the lower fetal P-selectin concentrations
in the pre-eclamptic group could be a protective mechanism
to limited endothelial damage to the fetus. The reduced
placental P-selectin expression in pre-eclampsia could also
contribute to lower fetal sP-selectin. In addition, the decreased
P-selectin could also be explained by the known reduction in
platelet numbers in pre-eclampsia (34). Furthermore, the inverse
relationship with AT1R, suggests this is independent of AT1R
expressed on platelets. Ang II can increase P-selectin expression
within the vascular wall (45) and thus increase atherosclerotic
plaque progression. Therefore, the reduced placental P-selectin
expression in pre-eclampsia could be a feedback mechanism to
limit this damage and is supported by this negative correlation
with AT1R.
Inspection of Figures 2A,B led us to suggest that the ratio
between maternal and fetal sE- or sP-selectin might differ
between normotensive and pre-eclamptic women, and in early
and late-onset pre-eclampsia. As Figure 3 shows, this is indeed
the case, again emphasizing a possible protective mechanism.
The lack of differences observed between groups in sL-
selectin in plasma may be because differences are only seen
in specific cell types, for example the decreased levels in pre-
eclampsia reported in neutrophils, T-cells, and monocytes (46).
However, although not significant, there did appear to be a trend
toward reduced maternal sL-selectin concentrations in the early-
onset pre-eclamptic group. This is in line with previous studies
where the majority of the pre-eclamptic samples measured were
from early-onset pre-eclampsia (23, 47). To investigate this
fully, future studies will examine whether any differences are
observed when leukocytes and platelets are isolated and analyzed
to confirm if the differences in this study are confirmed, or
were masked by measuring in whole plasma. In contrast, there
is increased placental expression in placenta from the early-
onset pre-eclampsia group, which is not reflected in parallel
increases in thematernal or fetal circulation. This again suggests a
possible protective mechanism, further supported by the positive
association seen with placental AT2R expression in the pre-
eclamptic group. It has been suggested that these lower levels
result in increased leukocyte activation as seen in some chronic
inflammatory states (e.g., chronic artery disease (48)). We can
thus speculate that the increased placental L-selectin in early-
onset pre-eclampsia could lead to increased leucocyte activation
and therefore atherosis in these placenta.
To conclude, this study is the first to report matchedmaternal,
fetal and placental expression of all 3 selectins in pre-eclampsia.
The increased E-selectins reflect the endothelial dysfunction,
characteristic of pre-eclampsia. In contrast, the reduced P-
selectins and the positive association with the placental AT2R
with both E-and L-selectin in pre-eclampsia could be a protective
mechanism to limit the endothelial dysfunction. Due to the roles
of the selectins, this observational study further supports the
importance of endothelial cells, platelets, and leucocytes in the
pathogenesis of pre-eclampsia.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Nottingham University Hospital Ethics Committee.
The patients/participants provided their written informed
consent to participate in this study.
AUTHOR CONTRIBUTIONS
HM, LK, MO, and GE developed and performed measurement
techniques, analyzed data, and wrote the manuscript. LK and
HM collected samples and clinical information. FB directed the
project, analyzed data, and assisted with writing the manuscript.
All authors provided critical reviews of the manuscript.
Frontiers in Medicine | www.frontiersin.org 6 June 2020 | Volume 7 | Article 270
Mistry et al. Selectins, Renin-Angiotensin System and Pre-eclampsia
ACKNOWLEDGMENTS
We thanks Heidi Jamin and Beatrice Rohrbach for running the
ELISA assays and all the women who participated in the study.
This work was supported by the British Heart Foundation Basic
Science Intermediate Basic Science Fellowship [FS/15/32/31604
to HM]. Some parts of the data, in an adapted form from this
manuscript has been published as a conference paper (49).
REFERENCES
1. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin
JM. The classification and diagnosis of the hypertensive disorders of
pregnancy: statement from the International Society for the Study of
Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. (2001) 20:IX-
XIV. doi: 10.3109/10641950109152635
2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia.
Lancet. (2010) 376:631–44. doi: 10.1016/S0140-6736(10)60279-6
3. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol.
(2009) 33:130–7. doi: 10.1053/j.semperi.2009.02.010
4. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk
of cardiovascular disease and cancer in later life: systematic review and
meta-analysis. BMJ. (2007) 335:974. doi: 10.1136/bmj.39335.385301.BE
5. Mistry HD, Kurlak LO, Mansour YT, Zurkinden L, Mohaupt MG,
Escher G. Increased maternal and fetal cholesterol efflux capacity and
placental CYP27A1 expression in preeclampsia. J Lipid Res. (2017) 58:1186–
95. doi: 10.1194/jlr.M071985
6. Mistry HD, Wilson V, Ramsay MM, Symonds ME, Broughton
Pipkin F. Reduced selenium concentrations and glutathione
peroxidase activity in pre-eclamptic pregnancies. Hypertension. (2008)
52:881–8. doi: 10.1161/HYPERTENSIONAHA.108.116103
7. Poston L. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep. (2006)
58 Suppl:69–74.
8. Poston L, Igosheva N, Mistry HD, Seed PT, Shennan AH, Rana S, et al. Role of
oxidative stress and antioxidant supplementation in pregnancy disorders. Am
J Clin Nutr. (2011) 94(6 Suppl):1980S−5S. doi: 10.3945/ajcn.110.001156
9. Campello E, Spiezia L, Radu CM, Dhima S, Visentin S, Valle FD,
et al. Circulating microparticles in umbilical cord blood in normal
pregnancy and pregnancy with preeclampsia. Thromb Res. (2015) 136:427–
31. doi: 10.1016/j.thromres.2015.05.029
10. Broughton Pipkin F. The renin-angiotensin system in pre-eclampsia. In: Lyall
F, Belfort M, editors. Pre-Eclampsia. Etiology Clinical Practice. Cambridge:
Cambridge University Press (2007) 78–91.
11. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. (1999)
340:115–26. doi: 10.1056/NEJM199901143400207
12. Williams PJ, Mistry HD, Innes BA, Bulmer JN, Broughton Pipkin
F. Expression of AT1R, AT2R and AT4R and their roles in
extravillous trophoblast invasion in the human. Placenta. (2010)
31:448–55. doi: 10.1016/j.placenta.2010.02.014
13. Farag E, Maheshwari K, Morgan J, Sakr Esa WA, Doyle DJ. An update of the
role of renin angiotensin in cardiovascular homeostasis. Anesth Analg. (2015)
120:275–92. doi: 10.1213/ANE.0000000000000528
14. Mistry HD, Kurlak LO, Broughton Pipkin F. The placental renin-angiotensin
system and oxidative stress in pre-eclampsia. Placenta. (2013) 34:182–
6. doi: 10.1016/j.placenta.2012.11.027
15. Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial
selectins: specialized glycoconjugates that mediate rolling and signaling under
flow. Blood. (2011) 118:6743–51. doi: 10.1182/blood-2011-07-343566
16. Kappelmayer J, Nagy B Jr. The interaction of selectins and PSGL-1 as a key
component in thrombus formation and cancer progression. Biomed Res Int.
(2017) 2017:6138145. doi: 10.1155/2017/6138145
17. Auvinen K, Jalkanen S, Salmi M. Expression and function of
endothelial selectins during human development. Immunology. (2014)
143:406–15. doi: 10.1111/imm.12318
18. Walcheck B, Moore KL, McEver RP, Kishimoto TK. Neutrophil-neutrophil
interactions under hydrodynamic shear stress involve L-selectin and
PSGL-1. A mechanism that amplifies initial leukocyte accumulation of
P-selectin in vitro. J Clin Invest. (1996) 98:1081–7. doi: 10.1172/JCI1
18888
19. Feng Y, Ma X, Deng L, Yao B, Xiong Y, Wu Y, et al. Role of selectins
and their ligands in human implantation stage. Glycobiology. (2017) 27:385–
91. doi: 10.1093/glycob/cwx009
20. Eskicioglu F, Lacin S, Ozbilgin K, Kose C. The role of selectins
in the first trimester pregnancy loss. Ginekol Pol. (2014)
85:287–93. doi: 10.17772/gp/1725
21. de la Sierra A, Larrousse M. Endothelial dysfunction is associated with
increased levels of biomarkers in essential hypertension. J Hum Hypertens.
(2010) 24:373–9. doi: 10.1038/jhh.2009.91
22. Carty DM, Anderson LA, Freeman DJ, Welsh PI, Brennand
JE, Dominiczak AF, et al. Early pregnancy soluble E-selectin
concentrations and risk of preeclampsia. J Hypertens. (2012)
30:954–9. doi: 10.1097/HJH.0b013e328352573b
23. Chaiworapongsa T, Romero R, Yoshimatsu J, Espinoza J, Kim YM, Park K, et
al. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia.
J Matern Fetal Neonatal Med. (2002) 12:19–27. doi: 10.1080/jmf.12.1.19.27
24. Veas CJ, Aguilera VC, Munoz IJ, Gallardo VI, Miguel PL, Gonzalez MA, et al.
Fetal endothelium dysfunction is associated with circulating maternal levels
of sE-selectin, sVCAM1, and sFlt-1 during pre-eclampsia. J Mat -Fetal Neon
Med. (2011) 24:1371–7. doi: 10.3109/14767058.2011.556204
25. Krauss T, Azab H, Dietrich M, Augustin HG. Fetal plasma levels
of circulating endothelial cell adhesion molecules in normal and
preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol. (1998)
78:41–5. doi: 10.1016/S0301-2115(98)00010-4
26. Docheva N, Romero R, Chaemsaithong P, Tarca AL, Bhatti G, Pacora
P, et al. The profiles of soluble adhesion molecules in the “great
obstetrical syndromes”(). J Matern Fetal Neonatal Med. (2019) 32:2113–
36. doi: 10.1080/14767058.2018.1427058
27. Nasrollahi S, Hoseini Panah SM, Tavilani H, Tavasoli S, Naderan M, Shoar
S. Antioxidant status and serum levels of selectins in pre-eclampsia. J Obstet
Gynaecol. (2015) 35:16–8. doi: 10.3109/01443615.2014.935710
28. Senchenkova EY, Russell J, Almeida-Paula LD, Harding JW, Granger DN.
Angiotensin II-mediated microvascular thrombosis. Hypertension. (2010)
56:1089–95. doi: 10.1161/HYPERTENSIONAHA.110.158220
29. Amano H, Ito Y, Ogawa F, Eshima K, Suzuki T, Oba K, et al. Angiotensin
II type 1A receptor signaling facilitates tumor metastasis formation through
P-selectin-mediated interaction of tumor cells with platelets and endothelial
cells. Am J Pathol. (2013) 182:553–64. doi: 10.1016/j.ajpath.2012.10.026
30. Alexandru N, Popov D, Georgescu A. Platelet dysfunction in vascular
pathologies and how can it be treated. Thromb Res. (2012) 129:116–
26. doi: 10.1016/j.thromres.2011.09.026
31. Ishikawa M, Sekizuka E, Yamaguchi N, Nakadate H, Terao S, Granger DN, et
al. Angiotensin II type 1 receptor signaling contributes to platelet-leukocyte-
endothelial cell interactions in the cerebral microvasculature. Am J Physiol
Heart Circ Physiol. (2007) 292:H2306–15. doi: 10.1152/ajpheart.00601.2006
32. Silva-Filho JL, SouzaMC, HenriquesMG,Morrot A, SavinoW, Caruso-Neves
C, et al. Renin-angiotensin system contributes to naive T-cell migration in
vivo. Arch Biochem Biophys. (2015) 573:1–13. doi: 10.1016/j.abb.2015.02.035
33. Ishikane S, Hosoda H, Nojiri T, Tokudome T, Mizutani T, Miura K, et
al. Angiotensin II promotes pulmonary metastasis of melanoma through
the activation of adhesion molecules in vascular endothelial cells. Biochem
Pharmacol. (2018) 154:136–47. doi: 10.1016/j.bcp.2018.04.012
34. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et
al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis
and management recommendations for international practice. Pregnancy
Hypertens. (2018) 13:291–310. doi: 10.1016/j.preghy.2018.05.004
35. Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM. The definition
of severe and early-onset preeclampsia. Statements from the International
Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy
Hypertens. (2013) 3:44–7. doi: 10.1016/j.preghy.2012.11.001
Frontiers in Medicine | www.frontiersin.org 7 June 2020 | Volume 7 | Article 270
Mistry et al. Selectins, Renin-Angiotensin System and Pre-eclampsia
36. Gardosi J, Chang A, Kalyan B, Sahota D, Symonds EM. Customised antenatal
growth charts. Lancet. (1992) 339:283–7. doi: 10.1016/0140-6736(92)91342-6
37. Mistry HD, McCallum LA, Kurlak LO, Greenwood IA, Broughton Pipkin F,
Tribe RM. Novel expression and regulation of voltage-dependent potassium
channels in placentas from women with preeclampsia. Hypertension. (2011)
58:497–504. doi: 10.1161/HYPERTENSIONAHA.111.173740
38. Chavarria ME, Lara-Gonzalez L, Garcia-Paleta Y, Vital-Reyes VS, Reyes
A. Adhesion molecules changes at 20 gestation weeks in pregnancies
complicated by preeclampsia. Eur J Obstet Gynecol Reprod Biol. (2008)
137:157–64. doi: 10.1016/j.ejogrb.2007.06.014
39. Chen X, Scholl TO. Maternal biomarkers of endothelial
dysfunction and preterm delivery. PLoS ONE. (2014)
9:e85716. doi: 10.1371/journal.pone.0085716
40. Shaw J, Tang Z, Schneider H, Salje K, Hansson SR, Guller S. Inflammatory
processes are specifically enhanced in endothelial cells by placental-derived
TNF-alpha: Implications in preeclampsia (PE). Placenta. (2016) 43:1–
8. doi: 10.1016/j.placenta.2016.04.015
41. Nussbaum C, Gloning A, Pruenster M, Frommhold D, Bierschenk
S, Genzel-Boroviczeny O, et al. Neutrophil and endothelial adhesive
function during human fetal ontogeny. J Leukoc Biol. (2013) 93:175–
84. doi: 10.1189/jlb.0912468
42. Oh IY, Yoon CH, Hur J, Kim JH, Kim TY, Lee CS, et al.
Involvement of E-selectin in recruitment of endothelial progenitor
cells and angiogenesis in ischemic muscle. Blood. (2007) 110:3891–
9. doi: 10.1182/blood-2006-10-048991
43. Brodowski L, Burlakov J, Hass S, von Kaisenberg C, von Versen-Hoynck F.
Impaired functional capacity of fetal endothelial cells in preeclampsia. PLoS
ONE. (2017) 12:e0178340. doi: 10.1371/journal.pone.0178340
44. Namsolleck P, Recarti C, Foulquier S, Steckelings UM, Unger T. AT(2)
receptor and tissue injury: therapeutic implications. Curr Hypertens Rep.
(2014) 16:416. doi: 10.1007/s11906-013-0416-6
45. Tayeh MA, Scicli AG. Angiotensin II and bradykinin regulate the expression
of P-selectin on the surface of endothelial cells in culture. Proc Assoc Am
Physicians. (1998) 110:412–21.
46. Luppi P, Tse H, Lain KY, Markovic N, Piganelli JD, DeLoia JA.
Preeclampsia activates circulating immune cells with engagement
of the NF-kappaB pathway. Am J Reprod Immunol. (2006)
56:135–44. doi: 10.1111/j.1600-0897.2006.00386.x
47. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and
preeclampsia both produce inflammatory changes in peripheral blood
leukocytes akin to those of sepsis. Am J Obstet Gynecol. (1998) 179:80–
6. doi: 10.1016/S0002-9378(98)70254-6
48. HaughtWH,Mansour M, Rothlein R, Kishimoto TK, Mainolfi EA, Hendricks
JB, et al. Alterations in circulating intercellular adhesion molecule-1 and L-
selectin: further evidence for chronic inflammation in ischemic heart disease.
Am Heart J. (1996) 132(1 Pt 1):1–8. doi: 10.1016/S0002-8703(96)90383-X
49. Kurlak LO, Hott-Ogalde MV, Scaife PJ, Escher G, Mistry HD.
Maternal and placental selectins in women with pre-eclampsia;
association with the renin-angiotensin system. Placenta. (2019)
83:e105. doi: 10.1016/j.placenta.2019.06.332
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Mistry, Ogalde, Broughton Pipkin, Escher and Kurlak. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Medicine | www.frontiersin.org 8 June 2020 | Volume 7 | Article 270
